Sarepta price target raised to $50 from $35 at Piper Jaffray
Piper Jaffray believes the FDA's request for additional information bodes well for accelerated approval of eteplirsen. The firm sees increased likelihood that Sarepta will be able to file an application for eteplirsen later this year and raised its price target for shares to $50 from $35. Piper reiterates an Overweight rating on Sarepta, whose shares were downgraded this morning at Leerink.
Sentiment: Strong Buy